CoChat
Sign Up
Cited by 237Schizophrenia research and treatmentPsychological Testing and AssessmentDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 16 of the 17 references it cites were found in a registry or an index.

Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial

Keefe, Richard S.E., Fox, Kolleen Hurley, Harvey, Philip D., Cucchiaro, Josephine, Siu, Cynthia, Loebel, Antony·2011·Schizophrenia Research
DOI 10.1016/j.schres.2010.09.015
Open this paper in CoChat — free account

Abstract

Objective The Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Project produced a battery of tests, the MATRICS Consensus Cognitive Battery (MCCB), designed to assess cognitive treatment effects in clinical trials of patients with schizophrenia. In validation studies, the MCCB demonstrated excellent reliability, minimal practice effects and significant correlations with measures of functional capacity. This study addresses whether the MCCB demonstrates these favorable characteristics when administered in the context of the type of large multi-site industry trial for which it was designed.Methods In a clinical trial comparing risperidone and lurasidone, 323 clinically-stable outpatients with schizophrenia at 29 sites were assessed with MCCB at screening and a median of 15days later at baseline. A measure of functional capacity, the UCSD Performance-based Skills Assessment-Brief (UPSA-B) was administered at baseline.Results All 323 (100%) patients had sufficient data for computing a composite score according to the MCCB criteria. The test-retest reliability of the MCCB composite score was excellent (ICC=0.88). The severity of cognitive impairment was T=24.7 (SD=12.1) at screening and T=26.7 (SD=12.4) at baseline. The MCCB composite score demonstrated a large correlation with the UPSA-B composite score (r=.60, df=304, p<.001). The practice effect on the composite score was small (z=0.18).Discussion In the context of a 29-site antipsychotic trial in stable outpatients with schizophrenia, the MCCB is sensitive to cognitive deficits in all domains, demonstrates excellent test-retest reliability and small practice effects, and is strongly correlated with a leading measure of functional capacity.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.schres.2010.09.015

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 17 references

1 of the 17 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Items 201–237 of 237

Related

See all

Metadata

Authors
Keefe, R. S. E., Fox, K. H., Harvey, P. D., Cucchiaro, J., Siu, C., & Loebel, A.
Affiliations
  • Duke University (US)
  • Verasci (United States) (US)
  • University of Miami (US)
  • Sunovion (United States) (US)
Corresponding author
Keefe, Richard S.E.
ORCID
Venue
Schizophrenia Research
Publisher
Elsevier BV
Published
2011-02
Volume
125
Issue
2-3
Pages
161-168
ISSN
0920-9964 (ISSN-L)
DOI
10.1016/j.schres.2010.09.015
OpenAlex
W2169310695
Cited by
237
References
17
Citations by year
2026: 14 · 2025: 25 · 2024: 15 · 2023: 11 · 2022: 15 · 2021: 9 · 2020: 12 · 2019: 14 · 2018: 14 · 2017: 10 · 2016: 13 · 2015: 16 · 2014: 22 · 2013: 20 · 2012: 14
FWCI
10.03
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Schizophrenia Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • GlaxoSmithKline
  • CHDI Foundation
  • H. Lundbeck A/S
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Applied Psychology › Psychological Testing and Assessment
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
MATRICS Consensus Cognitive Battery, schizophrenia
MeSH terms
Lurasidone Hydrochloride, Adult, Cognition Disorders, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Psychiatric Status Rating Scales, Psychometrics, Schizophrenia, Schizophrenic Psychology, Thiazoles, Antipsychotic Agents, Reproducibility of Results, Risperidone, Isoindoles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review